Oral semaglutide: difference between revisions
Diff·revision 20 → 21·08:11, 6 Oct 2025
Difference between revision 20 and revision 21 of Oral semaglutide. 2 lines changed; the page grew by 233 bytes.
| Revision 20 — 10:52, 14 Sep 2025 DulaglutideDug (talk) rm duplicated pharmacokinetics — the same figures appear in the infobox 4,349 bytes ±0 | Revision 21 — 08:11, 6 Oct 2025 AxisLabelAgda (talk) correct the molar mass — source gives the free-base figure, we had the salt 4,582 bytes +233 | ||
|---|---|---|---|
| 33 | Research-chemical supply of this formulation is uncommon, since a co-formulated tablet is a manufactured drug product rather than a bulk peptide, and reproducing it is a formulation exercise rather than a synthesis.{{r|reports}} | 33 | Research-chemical supply of this formulation is uncommon, since a co-formulated tablet is a manufactured drug product rather than a bulk peptide, and reproducing it is a formulation exercise rather than a synthesis.{{r|reports}} |
| 34 | 34 | ||
| + | 35 | Material sold as "oral semaglutide" in powder or capsule form outside licensed supply is not this product, whatever its peptide content, because the enhancer and the tablet architecture are what produce the absorption.{{r|usp1503}} | |
| + | 36 | ||
| 35 | == References == | 37 | == References == |
| 36 | {{reflist}} | 38 | {{reflist}} |